Fortress Adds New Rare Disease-Focused Subsidiary
Executive Summary
Cyprium joins Fortress’ growing company portfolio, which now includes nine subsidiaries focused on a broad range of disease. Fortress CEO Rosenwald aims to add one to two new companies a quarter under the Fortress umbrella.
You may also be interested in...
Sentynl Signs Deal With Fortress’ Cyprium For ‘De-Risked’ Rare Disease Drug
Deal Snapshot: Sentynl will pay $20m in upfront and regulatory milestone payments through FDA approval, while Cyprium will retain 100% ownership of the priority review voucher.
IPO Update: Returns Halved As Two Biopharmas Go Public In April; Unity Is May's First
Only two drug developers launched offerings in April and the average 2018 IPO return was just 9% – half the first quarter average – at the end of last month. Unity's May 1 offering was the 17th biopharma IPO this year.
Fortress Biotech: A Drug Financing Experiment Expands
Fortress Biotech has established nine subsidiary companies since 2013, each financed differently and each focused on an area of unmet need. Fortress CEO and longtime life sciences investor Lindsay Rosenwald lays out his ambitious plans for the future.